Special MRI may help surgeons remove more brain tumor

NCT ID NCT06448286

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This phase III trial compares a new type of MRI, called CEST MRI, to standard MRI for guiding surgery in 60 patients with newly diagnosed glioblastoma. The CEST MRI may detect tumor tissue that standard MRI misses, allowing surgeons to remove more of the cancer. The study will measure whether this leads to longer survival and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Chemical Exchange Saturation Transfer (CEST) Magnetic Resonance Imaging (MRI)
What this could lead to
If successful, this could lead to more complete tumor removal during glioblastoma surgery, potentially improving survival and quality of life.
What could go wrong
This is an early phase III trial with only 60 participants. The new MRI technique may not improve outcomes and could have unknown risks. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.